Wed, Oct 1, 2014, 6:46 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Immune Pharmaceuticals, Inc. Message Board

  • topaz_pathfinder topaz_pathfinder Aug 23, 2010 6:54 AM Flag

    FDA “Opinion”

    Not to forget, it is an “opinion” only, and no doubt, a blatant wrong one. This opinion is only based on the fact that it simply ignores proven medical facts, and, in addition, contesting the expertise of 30 European countries, that represent a leading position in medicine, such as e.g. UK, Sweden, Germany, France, Italy, Spain, Netherlands, Belgium, Austria, Ireland etc. etc.

    Therefore that's certainly not not written in stone and I do not think the last word is spoken here. Beyond that: it smells. The Co should carefully look on “interferences” of interested AML competitors, such as e.g. Glaxo.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Nothing real happened here: FDA officers gave their “opinion” which ignores medical facts, that's all ! This has neither a significant influence on the availability of this treatment for AML patients, nor on the basic value of the product. However, FDA has to answer if their opinion is influenced by interested competitors.

      The whole is a deja-vu of the first Ceplene request at EMEA. Also that time the market reacted with the same anger and distrust about this highly overpaid and incompetent EPCT mgmt. That's understanbdable, since this Talley is a proven champ in working with wrong timing and improper preparation, and this way killing existing market chances.

      Therefore in sum, it are here not the technical assets or medical facts. Every serious and diligent management would not have produced that disaster.

    • who know how to run a company

    • We currently see shorting and bashing: But in fact this FDA matter has no effect outside the US. Not at all in all the important markets in Europe, Asia or in the rest of the world. These markets are altogether by far larger than the US market.
      That does not excuse this overpaid Talley and his gang : Instead of at first securing standing and progress in these other markets, they preferred testing the moody FDA waters, needlessly adding the loser history a further failure.

    • The FDA guys have no clue about science, even medical representatives from Albania are better prepared.
      The whole game here looks similar to the “first round” with EMEA

    • Still it is their opinion, and it is the one that matters. Ceplene will not be in the USA for many years...if ever.

      I sold years ago, and have just been watching. I am glad I moved on when I did, but feel sorry for the rest of the longs here that stuck it out....

 
IMNP
3.15-0.21(-6.25%)Oct 1 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.